儿科出血性莫亚莫亚病:临床过程,治疗和结果
Qingbao Guo1, Manli Xie2, Jingchun Wang1
1Department of Neurosurgery, Xi'an No.9 Hospital Shaanxi, China.
Neurology
|January 29, 2026
概括
儿童的出血性莫亚莫亚病 (MMD) 具有侵略性,通常在老年女性中见到. 前动脉扩张和更高的入院残疾分数预测了更糟糕的结果和复发.
科学领域:
- 神经科学是一个神经科学.
- 儿科神经学 儿科神经学
- 血管神经学 血管神经学
背景情况:
- 儿科出血性莫亚莫亚病 (MMD) 由于高发病率而构成重大临床挑战.
- 具体与儿童出血性MMD相关的预后因素尚未确定.
- 了解这些因素对于改善患者的结果和指导治疗策略至关重要.
研究的目的:
- 定义儿科出血性MMD的临床过程.
- 确定与出血呈现和复发相关的因素.
- 评估一个患有MMD的大型儿科队列的长期结果.
主要方法:
- 小儿MMD患者 (2003-2023) 的回顾性队列研究.
- 由急性内出血 (不包括创伤/动脉瘤) 定义的出血性MMD.
- 数据包括苏苏基分期,PcomA/AChA扩张,mRS分数和复发事件;使用后勤回归和Cox模型进行分析.
主要成果:
- 出血性MMD队列 (117/1446名患者) 年龄较大,主要为女性.
- 出血性MMD的独立预测因子:AChA扩张 (aOR5.95),PcomA扩张 (aOR4.23),以及入院mRS≥2 (aOR2.38).
- AChA扩张强烈预测了复发性血液瘤 (HR 8.85);入院mRS ≥2预测了所有复发类型 (中风,血液瘤,心脏病发作).
结论:
- 出血性MMD是一种具有后侧附带脆弱性,女性占主导地位,呈现时年龄较大的攻击性亚型.
- 入院mRS得分≥2和ACHA扩张是不良结果的关键指标.
- 专注于后部循环评估对于结果分层和儿童MMD早期干预至关重要.
相关概念视频
01:24Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
01:22Alzheimer's Disease: Treatment
946
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
946
01:24Chronic Kidney Disease II: Clinical Manifestations
646
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
646
01:30Coronary Artery Disease III: Clinical Manifestations
369
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
369
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
939
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
939
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
485
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
485